Vertex Pharmaceuticals Incorporated
0QZU.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$130.38B
Close$
$269.51
44.7% downside
Current Fair Value
44.7% downsideOvervalued by 44.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $130.38 Billion |
|---|---|
| Enterprise Value | $124.23 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $15.46 |
| Beta | 0.61 |
| Outstanding Shares | 253,700,000 |
Return
| Return on Equity | 21.76% |
|---|---|
| Return on Assets | 16.06% |
| Return on Invested Capital | 21.70% |
Valuation & Multiples
| P/E Ratio | 29.45 |
|---|---|
| PEG | 454.7 |
| Price to Sales | 9.95 |
| Price to Book Ratio | 6.17 |
| Enterprise Value to Revenue | 9.87 |
| Enterprise Value to EBIT | 24.38 |
| Enterprise Value to Net Income | 28 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 3, 2026
EPS Estimate
$4.74
Average shareholder expectationRevenue Estimate
$3.23 B
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$4.76
Average shareholder expectationRevenue Estimate
$3.41 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Vertex Pharmaceuticals, Inc.
6,400 employees
CEO: Jeffrey Leiden Vertex Pharmaceuticals Incorporated is a biotechnology firm primarily dedicated to the discovery, development, and commercialization of therapies for cystic fibrosis (CF). The company offers a range of established CF treatments, such as ...